Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
ID: 338585Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/338585

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-123.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a Funding Opportunity Announcement (FOA) titled "Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)" aimed at fostering collaborations between academic and industrial researchers to advance innovative bioengineering technologies that address significant biomedical challenges. The initiative seeks applications that propose multidisciplinary partnerships with a mandatory inclusion of an industry partner, focusing on developing robust solutions that fulfill unmet medical needs within a timeframe of 5 to 10 years. This program is critical for enhancing biomedical research by leveraging diverse expertise to create technological innovations that can improve health outcomes. Interested applicants must submit their proposals by January 7, 2025, and can find additional information and application details at the NIH grants website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-123-Full-Announcement.html
    PAR-22-123.html
    The Department of Health and Human Services, through the National Institutes of Health, has issued a Funding Opportunity Announcement (FOA) titled "Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)." This initiative invites applications from academic and industrial partnerships to accelerate the development and adoption of innovative bioengineering technologies addressing major biomedical challenges. The program encourages multidisciplinary collaboration to create robust solutions that meet unfulfilled medical needs within 5 to 10 years. Eligible applicants include educational institutions, nonprofits, for-profit organizations, and government entities, with a mandatory inclusion of an industry partner in each application. The project must propose a research strategy with clear milestones and a detailed leadership plan that outlines collaborative efforts. Applications are rigorously evaluated based on significance, innovation, and the capability of the research team. The due dates for application submissions are specified, with the program running until January 2025. Overall, the FOA seeks to enhance biomedical research through strategic academic-industrial partnerships, tapping into diverse expertise to propel technological solutions for health improvements.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Biomedical-engineering Partnership with Industry (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the Biomedical-engineering Partnership with Industry (U01 Clinical Trial Not Allowed) aimed at fostering collaborations between academic and industrial organizations to develop innovative biomedical solutions. This initiative encourages the establishment of robust engineering solutions to address significant biomedical challenges, requiring applicants to form strategic alliances and outline a detailed plan with specific milestones to achieve results within 5-10 years. The anticipated funding opportunity announcement is expected to be published in February 2022, with applications due by May 2022, and the estimated award date is set for April 1, 2023. For further inquiries, interested parties can contact Dr. I. George Zubal at 301-827-5168 or via email at igeorge.zubal@nih.gov.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment" funding opportunity (FOA PAR-21-166). This initiative aims to foster collaborations between academic institutions and industry to translate scientific discoveries into practical diagnostic and therapeutic solutions, specifically targeting the development of methods or tools for disease prevention, diagnosis, and treatment. The program is particularly significant as it seeks to bridge gaps in healthcare technology and enhance the effectiveness of disease management across various settings, while explicitly excluding clinical trials. Eligible applicants can receive funding up to $499,000 per year for a maximum of five years, with applications due by January 8, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the funding announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-21-166.html.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment" (R01 - Clinical Trial Optional), aimed at fostering collaborations between academic and industrial organizations to develop innovative healthcare solutions. This initiative seeks to stimulate the translation of scientific discoveries into practical tools and methods for diagnosing and treating diseases, with a focus on interdisciplinary teamwork and addressing significant health challenges, particularly in low-resource settings. Eligible applicants can request funding up to $499,000 annually for a maximum project duration of five years, with the application deadline set for January 8, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-21-206.html.
    Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Bioengineering Research Grants (BRG) to encourage multidisciplinary collaborations that address significant biomedical challenges through innovative technologies. This funding opportunity aims to integrate life and physical sciences to accelerate the adoption of promising tools and methods in clinical or translational science, with a focus on projects that may involve clinical trials assessing functionality or performance in real-world settings. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and foreign entities, with no cost-sharing requirement, and applications are due by September 7, 2025. For more information, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-22-243.html.
    Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Bioengineering Research Grants (BRG), aimed at fostering multidisciplinary collaborations to address significant biomedical challenges. This funding opportunity encourages innovative research that integrates life and physical sciences to develop tools, methods, and technologies that can enhance healthcare delivery and medical practices. Eligible applicants include a diverse range of institutions, such as historically black colleges, tribal colleges, and community-based organizations, with projects allowed to span up to five years under the R01 grant mechanism. Interested parties should submit their applications electronically by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Blueprint Medtech: Small Business Translator (U44 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Blueprint Medtech: Small Business Translator (U44 - Clinical Trial Optional)" aimed at encouraging Small Business Concerns (SBCs) to develop therapeutic and diagnostic devices for disorders affecting the nervous and neuromuscular systems. This cooperative agreement program supports activities such as clinical prototype development, non-clinical safety testing, and preparation for regulatory submissions, facilitating the translation of innovative medical device technologies into clinical applications. The program emphasizes collaboration with NIH staff and aims to include diverse and underrepresented teams while adhering to rigorous compliance standards. Interested applicants must submit their proposals by September 28, 2024, and can find additional information at the NIH grants website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Notice of Funding Opportunity (NOFO) for the NIAID Clinical Trial Implementation Cooperative Agreement (U01), aimed at supporting high-risk clinical trials that enhance the understanding of human diseases. This funding opportunity encourages applications for investigator-initiated, milestone-driven clinical trials, with each application permitted to propose only one clinical trial that must demonstrate a hypothesis-driven approach. The initiative emphasizes the importance of mechanistic studies within clinical trials and requires a robust plan for managing trial complexity and participant safety. Interested applicants can find additional details and guidelines at the provided NIH link, with the earliest submission date set for April 12, 2024, and the application deadline on January 13, 2027. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems," aimed at fostering collaborations between academic institutions and industrial organizations to enhance imaging technologies for cancer diagnosis and treatment. This initiative seeks to translate scientific discoveries and engineering advancements into practical tools that address significant challenges in cancer research, focusing on the development and validation of imaging systems that improve detection and treatment monitoring. The grant offers a maximum budget of $500,000 per year for up to five years, with applications required to include at least one academic and one industrial investigator. Interested applicants can find more information and submit their proposals by the deadline of January 7, 2027, by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-259.html.
    Research Project Grant (Parent R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Research Project Grant (Parent R01 Clinical Trial Required) to support specified clinical research projects that align with the missions of various NIH institutes. Applicants are required to propose at least one clinical trial, focusing on significant health-related research areas, and must comply with the NIH Grants Policy Statement. This funding opportunity is crucial for advancing medical science and improving patient care, emphasizing innovation and scientific merit in addressing important health issues. The application deadline is January 7, 2025, and interested parties can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further inquiries. More details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PA-20-183.html.
    Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research," aimed at advancing innovative research in biomimetic tissue-engineered technologies for cancer. This initiative seeks to support collaborative, multidisciplinary projects that integrate regenerative medicine, tissue engineering, and cancer biology to develop advanced in vitro and ex vivo models that accurately mimic human cancer pathophysiology. The funding opportunity is crucial for enhancing cancer research methodologies and understanding disease mechanisms, with a maximum budget of $400,000 per year and a project duration of up to five years. Interested applicants must submit their proposals electronically via Grants.gov by May 8, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.